Supply and procurement roadmaps

in page functions

Supply and procurement roadmaps help guide Gavi’s market shaping efforts by analysing the dynamics of each vaccine or other immunisation product market.

Bio Manguinhos - vials inside production line

Credit: Bernardo Portella/2016.

Roadmaps determine Gavi’s long-term market ambition for each vaccine or immunisation product. They present both a short- and long-term view of how we would like the market to evolve for a particular vaccine or product, and identify mechanisms that can help to influence it.

Gavi funds the global oral cholera vaccine stockpile, managed by the International Coordination Group. This document is the public summary of the supply and procurement roadmap for cholera vaccine.

Gavi opened a funding window for human papillomavirus (HPV) vaccines in 2012. The public summary of the HPV vaccine roadmap gives an overview of the market dynamics for this vaccine.

Gavi established the Cold Chain Equipment Optimisation Platform (CCEOP) in June 2015 as a strategic and targeted approach to address the challenges of improving the vaccine cold chain with higher-performing equipment. This document provides a summary of the supply and procurement roadmap for two CCE product categories: Ice-lined (ILR) & Solar Direct Drive (SDD) refrigerators/ freezers.

In 2013, the Gavi Board decided to fund the introduction of inactivated polio vaccine (IPV) in all Gavi-supported countries. This document is the public summary of the supply and procurement roadmap for IPV.

At its November 2013 Board meeting, the Vaccine Alliance opened a funding window for Japanese encephalitis (JE) catch-up campaigns in endemic countries. Download the public summary of the supply and procurement roadmap to learn more about Gavi’s market shaping objectives for the JE vaccine market.

Gavi supports meningococcal vaccines for use in campaigns and routine immunisation in endemic countries in Africa. This document is the public summary of the supply and procurement roadmap for meningococcal vaccine.

Gavi’s engagement on measles dates to 2004 and rubella support began in 2011 through the measles-rubella (MR) vaccine. By the end of 2016, Gavi had supported 50 countries with MR programmes. This public summary of the supply and procurement roadmap describes the market, and outlines Gavi’s market shaping ambitions for MR vaccines.

The introduction of hepatitis B and Haemophilus influenzae type b vaccination in all Gavi-supported countries through the five-in-one pentavalent vaccine is one of Gavi’s most significant achievements. This document provides a summary of the supply and procurement roadmap for pentavalent vaccines.

Gavi has supported routine introductions with pneumococcal vaccine since 2009. Find out more about the pneumococcal vaccine market, and Gavi’s approach to shaping it, in the public summary of the vaccine roadmap.

Rotavirus is the leading cause of severe diarrhoea in children under five years of age worldwide. This document is the public summary of the supply and procurement roadmap for rotavirus vaccine.

Gavi has been engaged in yellow fever (YF) vaccination since 2001 in support of WHO efforts to control the disease. This document is the public summary of the supply and procurement roadmap for yellow fever vaccine.

 

>54 million

Our support has contributed to immunising over 54 million children against rotavirus diarrhoea. By the end of 2016, 40 countries had introduced the vaccine with support from the Vaccine Alliance.

WHO/UNICEF 2017

More facts...

close icon

modal window here